← All trials
NCT05491200
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 22, 2022
- Primary completion
- Aug 1, 2026
- Completion date
- Aug 1, 2028
- First posted
- Aug 8, 2022
- Last posted
- Sep 19, 2022
- Enrollment
- 1608
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Research Maatschap Cardiologen Rotterdam ZuidLead sponsor
- AbbottCollaborator
- Research Maatschap Cardiologen Rotterdam ZuidOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.